Treatment

The phase 2 AZUR-1 trial has met its main goal, showing that dostarlimab (Jemperli) alone can produce a lasting complete response in patients with stage II/III dMMR/MSI-H locally advanced rectal cancer. An interim analysis found that many patients had no detectable signs of cancer 12 months or longer after starting treatment. The results suggest that […]

New data show that zoldonrasib (RMC-9805), an oral RAS G12D-targeted therapy, produced promising results in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) carrying a RAS G12D mutation. In previously untreated patients, zoldonrasib combined with modified FOLFIRINOX achieved an objective response rate of 82%, while the combination with gemcitabine plus nab-paclitaxel reached 61%. Disease control rates

New data suggest that the survival benefit of DCVax-L for patients with glioblastoma (GBM) is greater than previously reported. The original phase 3 analysis showed that DCVax-L improved median overall survival by 2.8 months. However, a new analysis using individual patient data from three randomized clinical trials found that the actual survival benefit ranged from

Results from the phase 3 ELEVATE trial show that ensartinib (Ensacove) significantly reduced the risk of cancer recurrence in patients with completely resected stage IB to IIIB ALK-positive non-small cell lung cancer (NSCLC) after chemotherapy. Among patients with stage II to IIIB disease, the 24-month disease-free survival (DFS) rate was 86.4% with ensartinib, compared with

The oral drug INCB123667 showed encouraging early results in patients with platinum-resistant ovarian cancer whose tumors overexpress cyclin E1, a protein linked to poor outcomes. In a Phase 1 trial, 14 patients receiving a 100-mg daily dose achieved an overall response rate of 35.7%, with all responses being partial. The disease control rate was 71.4%,

Updated results from the CIRCULATE-Japan GALAXY study show that a blood test for circulating tumor DNA (ctDNA) can help identify which patients benefit from chemotherapy after surgery for colorectal cancer liver metastases. Among patients who had surgery first, those with detectable ctDNA after surgery gained major benefits from adjuvant chemotherapy. Their four-year overall survival rate

A retrospective analysis from the phase 3 ATOMIC trial suggests that patients with stage III dMMR colon cancer may benefit most from adding Atezolizumab to standard FOLFOX chemotherapy when they are able to complete more than six cycles of treatment. Patients who received more than six cycles of FOLFOX plus atezolizumab had a significantly lower

Results from the phase 2 eNRGy trial, published in the Journal of Clinical Oncology, supported the FDA approval of Zenocutuzumab as a second-line treatment for patients with advanced NRG1-positive Cholangiocarcinoma. The study included 22 patients whose cancer had progressed after previous treatment. Zenocutuzumab achieved an objective response rate of 36.8%, compared with about 5% historically

Botensilimab plus balstilimab showed encouraging long-term results in patients with heavily pretreated microsatellite-stable (MSS) metastatic colorectal cancer without active liver metastases, according to three-year follow-up from the phase 1b C-800-01 trial. Among 123 patients, median overall survival reached 21.2 months, nearly double the historical 10–14 months seen with standard later-line treatments. The objective response rate

New clinical trial results presented at the 2026 ESMO GI Cancers Congress suggest that zoldonrasib-based treatments may significantly improve outcomes for patients with KRAS G12D-mutated metastatic pancreatic ductal adenocarcinoma (PDAC). In previously untreated patients, zoldonrasib combined with modified FOLFIRINOX achieved an objective response rate of 82% and a disease control rate of 96%. When combined